Rochester, NY – November 21, 2024 – A groundbreaking study on exosome lyophilization has revealed alarming insights about the process’s impact on the integrity and functionality of exosomes, unveiling major implications for the regenerative aesthetics industry. The findings were presented by Dr. Michael Heke, PhD, Managing Director and Scientific Officer at AT Venture Center™ at the 9th International Congress of Medical Excellence in Dermatology & Aesthetic Medicine (MEIDAM) in Dubai. This pivotal research, led by Dr. Carla Mazzeo, PhD, a globally recognized exosome expert with over 20 years of experience, brings to light critical flaws in current exosome preservation methods, particularly lyophilization (freeze-drying), a common technique used for creating shelf-stable exosome products. [Read more…]
Allogeneic vs. Autologous Treatments: Definitions and Differences
What is the difference between an allogeneic and autologous treatment? Whether it is a stem cell treatment, a bone marrow transplant, or another type of cellular therapy, allogeneic means “from another person” while autologous means “from oneself.”
Let’s dig into this in more detail and explain why both of these approaches are commonly used within medicine.
[Read more…]
The Definitive Guide To Calculating Market Size
This article explores multiple methodologies for how to calculate a market size, including top-down and bottom-up approaches. [Read more…]
From Feeder-free to Coating-free, DuoGenic StemCells corporation has developed the next generation hPSC culture medium: DuoESy.
1. Introduction: Regenerative Medicine in Taiwan
Taiwan is famous for its semiconductor, night markets and pearl milk tea. But few people know that the public health insurance, medical technique and cell therapy are also flourishing.
In 2018, Taiwan government partially lifted the regulation on cell therapy with a positive list according to the “Regulations of Special Medical Techniques”. The permitted cell types include autologous immune cell (NK, CIK etc.), chondrocyte, fibroblast, ADSC and BM-MSC for specific indications respectively. [Read more…]
EVerZom achieves first bioproduction of clinical grade stem cell-derived exosomes in large scale bioreactors in partnership with the French Blood Establishment (EFS) with unprecedented yields
-
The disruptive, proprietary technology developed by EVerZom offers a yield 100 times higher than traditional methods.
-
This innovation has just been tech-transferred and validated in a GMP-grade biomanufacturing environment.
-
This first clinical batch will enable EVerZom to initiate regulatory non-clinical studies of its first drug candidate EVerGelTM.
- « Previous Page
- 1
- …
- 71
- 72
- 73
- 74
- 75
- …
- 334
- Next Page »